

PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

				Application Number	10/630,590		
TRANSMITTAL FORM			Filing Date	July 29, 2003 LU, PETER S.			
			First Named Inventor				
			Group Art Unit				
(to be used for all correspondence after initial filing)				Examiner Name			
Total Number of Pages in This Submission 3 + refs.			Attorney Docket Number	VITA-008			
	Total Walned of T	ages in This Cashillesia		ES (check all that apply)			
	Extension of Tin Express Abando Information Disc Certified Copy of Documents Response to Mis Incomplete Appl	ned eply declaration(s) ne Request onment Request closure Statement of Priority ssing Parts/	Assign (for an Drawin Licens Petitio Provis Power Chang Addre Reque	ament Papers Application) ng(s) sing-related Papers n n to Convert to a ional Application of Attorney, Revocation ge of Correspondence	1. 2. 3.	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): PTO/SB/08A Copies of non-patent cited references Postcard	
	Т	SIGNA	TURE OF APPI	LICANT, ATTORNEY, OF	RAGENT		
	Signing Attorney/Agent (Reg. No.) JAMES S. KEDDIE, PH.D., 48,920 BOXICEVIC, FIELD & FRANCIS/LLP						
Signature	e	James	5 N	of the			
Date	Date September 9, 2003						
EXPRESS MAIL LABEL NO. EV333999061US							

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV333999061US

INFORMATION	Attorney Docket	VITA-0
DISCLOSURE STATEMENT	First Named Inventor	LU, PE
	Application Number	10/630,
	Confirmation No.	
		1

Address to: Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Attorney Docket	VITA-008
First Named Inventor	LU, PETER S.
Application Number	10/630,590
Confirmation No.	
Filing Date	July 29, 2003
Group Art Unit	
Examiner Name	
Title: 'METHODS O	F DIAGNOSING CERVICAL

"METHODS OF DIAGNOSING CERVICAL CANCER"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. VITA-008 may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: September 9, 2003

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Dv.

James S. Keddie, Ph.D. Registration No. 48,920 SEP 0 9 2003

Examiner

Signature

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Stitute for form 1449A/PTO			Complete if Known					
4.2	INFORMATION DISCLOSURE				Application Number Filing Date		10/630,590 July 29, 2003	
1								
	STATI	EMENT BY APPLICA	ANT		First Named Inventor Art Unit Examiner Name		ETER S.	
				Art Unit				
	(use	as many sheets as necessar	v)					
Sheet		1 of	1		Docket Number	VITA-	008	
ļ			II S P	-l	DCUMENTS	1		
		Document Number	0.3.17	AILINI DO	COMEINIS		Pages, Columns, Lines, Whe	
Examiner Initials'	Cite No. ¹	Number-Kind Code ² (if known,	l l	ation Date D-YYYY	Name of Patentee or Applicant of Cited Document			
		US- 4,777,239						
		US- 5,415,995						
		US- 5,648,459						
		US- 5,665,535					The Attribute of the Control of the	
		US- 5,753,233						
		US- 5,876,723						
		US- 6,322,794						
		US- 6,344,314			ļ		The state of the s	
	<u>.</u>	US- 6,391,539						
		OTHER PR	OR ART—NO	N PATEN	T LITERATURE D	OCUM	ENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),					T ²	
		GARDIOL et al., ONCOGENIC HUMAN PAPILLOMAVIRUS E6 PROTEINS TARGET THE DISCS LARGE TUMOUR SUPPRESSOR FRO PROTEASOME-MEDIATED DEGRADATION, Oncogene, (1999), 18:5487-96						
		GLAUNSINGER et al., INTERACTIONS OF THE PDZ-PROTEIN MAGI-1 WITH ADENOVIRUS E4-ORF1 AND HIGH-RISK PAPILLOMAVIRUS E6 ONCOPROTEINS, Oncogene, (2000), 19:5270-80						
		KIYONO et al., BINDING OF HIGH-RISK HUMAN PAPILLOMAVIRUS E6 ONCOPROTEINS TO THE HUMAN HOMOLOGUE OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:11612-6						
		LEE et al., BINDING OF HUMAN VIRUS ONCOPROTEINS TO HDLG/SAP97, A MAMMALIAN HOMOLOG OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:6670-5						
		MESCHEDE et al., ANTIBODIES AGAINST EARLY PROTEINS OF HUMAN PAPILLOMAVIRUSES AS DIAGNOSTIC MARKERS FOR INVASIVE CERVICAL CANCER, J. Clin. Microbiol., (1998), 36:475-80						
		MUNGER et al., THE ROLE OF HUMAN PAPILLOMAVIRUSES IN HUMAN CANCERS, Front. Biosci., (2002), 7:d641-9						
		PIM et al., HPV-18 E6*I PROTEIN MODULATES THE E6-DIRECTED DEGRADATION OF P53 BY BINDING TO FULL-LENGTH HPV-18 E6, Oncogene, (1999), 18:7403-8						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Date

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**